生物试剂
>
生化试剂
>
信号通路
> 软木肟酸
加入收藏 取消收藏

软木肟酸  ≥98%

促销价¥{{model.attbuying.price}}

市场价¥0.00

累计销量0 累计评价0 人评论

别称 {{model.alias}}
中文名称 {{model.name}}
英文名称 {{model.enname}}
品牌 {{model.brand}}
CAS {{model.cas}}
分子式
分子量 {{model.molecularweight}}
MDL {{model.mdl}}
货号 {{model.procode}}
数量

+ -

件 库存{{model.attbuying.number}}件
立即购买 加入购物车 下载说明书

看了又看
包装规格：1g in glass bottle
溶解性：溶于DMSO（50 mg/mL 超声）
产品描述：基本信息 产品编号：S10708  产品名称：Suberoyl bis-hydroxamic acid CAS: 38937-66-5   储存条件 粉末 2-8℃ 四年 分子式： C8H16N2O4 溶于液体 -80℃ 两年 分子量 204.22     化学名：  N,8-dihydroxy-8-(hydroxyamino)octanamide   Solubility (25°C)   体外 DMSO 41mg/mL (200.76mM) Ethanol Insoluble Water 4mg/mL (19.58mM) 体内 现配现用   ＜1mg/ml表示微溶或不溶。 普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。   制备储备液   浓度   溶液体积 质量   1mg   5mg   10mg 1mM 4.8967mL 24.4834mL 48.9668mL 5mM 0.9793mL 4.8967mL 9.7934mL 10mM 0.4897mL 2.4483mL 4.8967mL   生物活性 产品描述 一种竞争性且可透过细胞的 HDAC1 和 HDAC3 抑制剂，ID50 值分别为 0.25μM 和 0.30μM。 靶点/IC50 HDAC1 (Cell-free assay) 0.25μM HDAC3 (Cell-free assay) 0.3μM   体外研究 Suberoyl bis-hydroxamic acid (10, 20 or 50μM; 24 hours) combination with TRAIL improves apoptosis extent, and when TRAIL is combined with 20μM SBHA (itself causing only 10–15% apoptosis), resulting in 45–50% cell death. Suberoyl bis-hydroxamic acid (20-50μM; 10-20 hours) alone has little effect on the expression of the proteins Bcl-xL, Mcl-1, and has albeit mildeffect on Bax. When it combines with TRAIL,which increases the ratio of relative protein expression of BclxL and Bax in early periods, while the change in the ratio of Mcl-1 and Bax increases later in MM-BI and Ist-Mes2 cells. Suberoyl bis-hydroxamic acid (30μM; 6 hours) causes accumulation of acetylated histone H4 in MEL cells. Apoptosis Analysis Cell Line: MM-BI and Ist-Mes2 cells Concentration: 10μM, 20μM or 50μM Incubation Time: 24 hours Result: Showed a cooperative effect in cell apoptosis.   体内研究 Suberoyl bis-hydroxamic acid (intraperitoneal injection; 200 mg/kg; every 2 days; 12 days) reveals a marked increase in the active form of Notch1 (NICD) with a concomitant decrease in ASCL1. It reduces the MTC tumor growth Animal Model: Nude mice injected with human MTC cells Dosage: 200mg/kg Administration: Intraperitoneal injection; every 2 days; 12 days Result: Resulted in an average 55% inhibition of tumor growth in SBHA treatment group.
保存条件：2-8℃

猜你喜欢